D. Keating

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr et al. · New England Journal of Medicine · 2018 · 727 citations · Full text

Pharmacy, Molecular Genetics, Pharmacotherapy +13

Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis

Conor Hurson, Joseph S. Butler, D. Keating et al. · BMC Musculoskeletal Disorders · 2007 · 111 citations · Full text

Medicine, Endocrinology, Molecular Biology +17

Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry

Victor Khou, James Anderson, Geoff Strange et al. · Respirology · 2020 · 87 citations · Full text

Medicine, Cardiology, Clinical Sciences +8

Lung Transplantation in Pulmonary Fibrosis: Challenging Early Outcomes Counterbalanced by Surprisingly Good Outcomes Beyond 15 Years

D. Keating, Bronwyn Levvey, Tom Kotsimbos et al. · Transplantation Proceedings · 2009 · 68 citations

Medicine, Surgery, Pulmonology +12

Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment

Deirdre Edgeworth, D. Keating, Matthew J. Ellis et al. · Clinical Science · 2017 · 61 citations

Medicine, Physiology, Exercise Physiology +16